Low Dose of Pizotifen in Migraine Prevention: A Comparison with Topiramate


  • Mazin M Mohsin neuromedicine specialist /Al Sadic teaching hospital, Babylon, Iraq.


Migraine Prevention, Pizotifen, topiramate


Background & Objective: Pizotifen is an alternative option for prophylactic treatment of migraine headache. This study aims to compare the efficacy and safety of pizotifen with topiramate; one of the most-widely used drugs in migraine prevention. Methods: This was a single blind, randomized, parallel-group study. After a 4-week baseline evaluation, patients with episodic migraine were randomly assigned to get either to piramate or pizotifen for a period of 12 weeks. Patients were asked to fill a headache diary through the study. Headache characteristics and the possible side effects were evaluated throughout and at the end of trial. Results: Sixty patients aged 20 to 49 were recruited to the study. With both drugs, the frequency, intensity and duration of headaches were significantly reduced (p < 0.05). Except for headache duration, pizotifen was significantly superior to  topiramate in the headache parameters assessed. Total reported side effects were initially higher inpatients who received pizotifen (37 vs. 22; P= 0.038); however, persistent side effects were lower for pizotifen (6 vs. 10; P= 0.22).Conclusions: The results of this study suggest that pizotifen is a safe and effective drug in migraine prevention.


Download data is not yet available.



How to Cite

M. M. . Mohsin, “Low Dose of Pizotifen in Migraine Prevention: A Comparison with Topiramate”, JUBPAS, vol. 28, no. 3, pp. 312-320, Dec. 2020.